269. Pyogenic arthritis Clinical trials / Disease details
Clinical trials : 23 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02366260 (ClinicalTrials.gov) | February 2015 | 11/2/2015 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Gevokizumab;Drug: Placebo | MedDerm Associates | XOMA (US) LLC | Recruiting | 18 Years | N/A | Both | 5 | Phase 3 | United States |
| 2 | NCT02326740 (ClinicalTrials.gov) | December 2014 | 22/12/2014 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 9 | Phase 3 | United States;Australia;Canada |
| 3 | NCT02315417 (ClinicalTrials.gov) | November 2014 | 5/12/2014 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 16 | Phase 3 | United States |
| 4 | NCT02318914 (ClinicalTrials.gov) | November 2014 | 8/12/2014 | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 15 | Phase 3 | United States;Australia;Canada |
| 5 | NCT01882504 (ClinicalTrials.gov) | May 2013 | 17/6/2013 | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum | An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab | XOMA (US) LLC | NULL | Completed | 18 Years | N/A | Both | 8 | Phase 2 | United States |